Literature DB >> 12036639

Prophylactic intracameral cefuroxime. Efficacy in preventing endophthalmitis after cataract surgery.

Per G Montan1, Gisela Wejde, Gabor Koranyi, Margareta Rylander.   

Abstract

PURPOSE: To evaluate the efficacy of prophylactic intracameral cefuroxime in preventing endophthalmitis in cataract surgery.
SETTING: Department of Ophthalmology, St. Eriks Hospital, Stockholm, Sweden.
METHODS: In a noncontrolled retrospective observational study, all cases of recorded postoperative endophthalmitis were related to the total number of uncombined cataract procedures from January 1996 to December 2000.
RESULTS: Twenty cases of postoperative endophthalmitis occurred in 32180 procedures, yielding an overall rate of 0.06%. Cefuroxime-resistant organisms accounted for 12 of 13 culture-positive cases, and enterococci were the most common etiology.
CONCLUSIONS: Intracameral cefuroxime 1 mg appeared to effectively inhibit sensitive bacterial strains and was associated with a low frequency of postoperative endophthalmitis. The causative organisms of future incidents of postoperative endophthalmitis will determine whether the present protocol must be reappraised.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036639     DOI: 10.1016/s0886-3350(01)01269-x

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  33 in total

Review 1.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.

Authors:  Emily W Gower; Kristina Lindsley; Samantha E Tulenko; Afshan A Nanji; Ilya Leyngold; Peter J McDonnell
Journal:  Cochrane Database Syst Rev       Date:  2017-02-13

2.  Microbiology and visual outcomes of culture-positive bacterial endophthalmitis in Oxford, UK.

Authors:  A Gupta; H O Orlans; S J Hornby; I C J W Bowler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-11       Impact factor: 3.117

3.  Incidence of post-cataract endophthalmitis with intracameral cefuroxime.

Authors:  Colin S H Tan; Louis W Lim; Vernon S Chow
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-05       Impact factor: 3.117

Review 4.  Prophylaxis of postoperative endophthalmitis following cataract surgery: current status and future directions.

Authors:  Robert E Fintelmann; Ayman Naseri
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

5.  Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.

Authors:  Randy C Bowen; Andrew Xingyu Zhou; Sailaja Bondalapati; Thomas W Lawyer; Karisa B Snow; Patrick R Evans; Tyler Bardsley; Mary McFarland; Matthew Kliethermes; Dallas Shi; Christina A Mamalis; Tom Greene; Christopher J Rudnisky; Balamurali Krishna Ambati
Journal:  Br J Ophthalmol       Date:  2018-01-11       Impact factor: 4.638

Review 6.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.

Authors:  Emily W Gower; Kristina Lindsley; Afshan A Nanji; Ilya Leyngold; Peter J McDonnell
Journal:  Cochrane Database Syst Rev       Date:  2013-07-15

7.  Intracameral vancomycin following cataract surgery: An eleven-year study.

Authors:  Deepa R Anijeet; Prasad Palimar; Clive O Peckar
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 8.  Intracameral cefuroxime: prophylaxis of postoperative endophthalmitis after cataract surgery.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

9.  Transient macular edema after intracameral injection of a moderately elevated dose of cefuroxime during phacoemulsification surgery.

Authors:  David C Wong; Michael D Waxman; Lisa J Herrinton; Neal H Shorstein
Journal:  JAMA Ophthalmol       Date:  2015-10       Impact factor: 7.389

10.  Comparative outcomes of pars plana vitrectomy in acute postoperative endophthalmitis with 25-gauge and 20-gauge techniques.

Authors:  Tugrul Altan; Ziya Kapran; Ilker Eser; Nur Acar; Yaprak Banu Unver; Serap Yurttaser
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.